FDA-approved
Skin & aging
Daptomycin
Evidence
FDA approved
Class
Cyclic lipopeptide antibiotic
KEY TAKEAWAY
Daptomycin is a cyclic lipopeptide produced by the soil bacterium Streptomyces roseosporus. It is sold as Cubicin. The FDA approved daptomycin in 2003 for complicated skin infections and later for Staphylococcus aureus bloodstream infections.
Written by the Veylo editorial team · Updated
November 2026
What it is
Cyclic lipopeptide antibiotic
Approved for
Complicated skin infections and bloodstream infections caused by gram-positive bacteria
Key fact
The FDA approved daptomycin in 2003 for complicated skin infections and later for Staphylococcus aureus bloodstream infections.
Route
Intravenous injection or infusion
Evidence strength
FDA approved
Daptomycin is a cyclic lipopeptide produced by the soil bacterium Streptomyces roseosporus. It is sold as Cubicin.
It inserts into the membranes of gram-positive bacteria and makes them lose their electrical potential, which kills the cell.
The FDA approved daptomycin in 2003 for complicated skin infections and later for Staphylococcus aureus bloodstream infections.
Complicated skin infections and bloodstream infections caused by gram-positive bacteria.
Muscle pain and a rise in the muscle enzyme creatine kinase can occur, so muscle symptoms are monitored. Eosinophilic pneumonia is rare but serious.
U.S. FDA prescribing information for Daptomycin. DailyMed, National Library of Medicine.
Veylo content is educational and not medical advice. Peptides that are not FDA-approved are not approved for the uses described.